Charles E. Geyer, MD, FACP

Lois E. and Carl A. Davis Centennial Chair in Cancer Research, Cancer Center
Professor of Medicine in Oncology, Academic Institute
Full Clinical Member, Research Institute
Deputy Director, Cancer Center
Houston Methodist


Biography

Charles E. Geyer, Jr., is Deputy Director of the Houston Methodist Cancer Center and has devoted most of his academic career on the design and conduct of multi-institutional, phase III clinical trials in breast cancer with a focus on the development of HER2 targeted therapies.  He has served in several leadership positions for the National Surgical Adjuvant Breast and Bowel Project (NSABP) which include vice-chair of the Breast Committee from 1999 until 2007, Associate Director of Medical Affairs from 2002 to 2006 and Director of Medical Affairs for NSABP from 2006 to 2011. In 2008, he was appointed as a founding Co-chair for the NCI Cancer Treatment Evaluation Program Breast Cancer Steering Committee and received a Director’s Award at the completion of his tenure in 2011. 

He earned his bachelor’s and doctoral degrees from Texas Tech University in Lubbock, Texas and completed his internal medicine residency and medical oncology fellowship at Baylor College of Medicine Affiliated Hospitals in Houston, Texas.

Description of Research

Currently he serves as vice chair of the NRG Breast Committee and chair of the NSABP Foundation Breast Cancer Committee.  Dr. Geyer served as study PI on the KATHERINE trial and study co-chair for the OlympiA trial, a global phase III study of olaparib as adjuvant therapy for patients with germline BRCA mutations and high risk early breast cancer.  He is also PI for NRG BR004, a trial evaluating atezolizumab in first-line therapy of HER2 positive metastatic breast cancer, and co-PI for NSABP B-59/GEPARDOUZE evaluating atezolizumab as neoadjuvant and adjuvant therapy in combination with chemotherapy for early stage TNBC.  Dr. Geyer has co-authored over 80 peer-reviewed manuscripts including results of several landmark phase 3 trials conducted by the NSABP. 

Areas Of Expertise

Immunotherapy HER2 positive breast cancer Clinical trials in early breast cancer
Education & Training

Residency, Baylor College of Medicine
Clinical Fellowship, Baylor College of Medicine
MD, Texas Tech University Health Sciences Center School of Medicine
Publications

Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer
Conte, PF, Schneeweiss, A, Loibl, S, Mamounas, EP, von Minckwitz, G, Mano, MS, Untch, M, Huang, CS, Wolmark, N, Rastogi, P, D’Hondt, V, Redondo, A, Stamatovic, L, Bonnefoi, H, Castro-Salguero, H, Fischer, HH, Wahl, T, Song, C, Boulet, T, Trask, P & Geyer, CE 2020, Cancer, vol. 126, no. 13, pp. 3132-3139. https://doi.org/10.1002/cncr.32873

Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx
Wagner, LI, Gray, RJ, Sparano, JA, Whelan, TJ, Garcia, SF, Yanez, B, Tevaarwerk, AJ, Carlos, RC, Albain, KS, Olson, JA, Goetz, MP, Pritchard, KI, Hayes, DF, Geyer, CE, Dees, EC, McCaskill-Stevens, WJ, Minasian, LM, Sledge, GW & Cella, D 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 17, pp. 1875-1886. https://doi.org/10.1200/JCO.19.01866

Clinical Outcomes in Early Breast Cancer with a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial
Sparano, JA, Gray, RJ, Makower, DF, Albain, KS, Saphner, TJ, Badve, SS, Wagner, LI, Kaklamani, VG, Keane, MM, Gomez, HL, Reddy, PS, Goggins, TF, Mayer, IA, Toppmeyer, DL, Brufsky, AM, Goetz, MP, Berenberg, JL, Mahalcioiu, C, Desbiens, C, Hayes, DF, Dees, EC, Geyer, C, Olson, JA, Wood, WC, Lively, T, Paik, S, Ellis, MJ, Abrams, J & Sledge, GW 2020, JAMA oncology, vol. 6, no. 3, pp. 367-374. https://doi.org/10.1001/jamaoncol.2019.4794

Breast Conservation after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results from the BrighTNess Randomized Clinical Trial
Golshan, M, Loibl, S, Wong, SM, Houber, JB, OShaughnessy, J, Rugo, HS, Wolmark, N, McKee, MD, Maag, D, Sullivan, DM, Metzger-Filho, O, Von Minckwitz, G, Geyer, CE, Sikov, WM & Untch, M 2020, JAMA Surgery, vol. 155, no. 3, e195410. https://doi.org/10.1001/jamasurg.2019.5410

NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+
Fehrenbacher, L, Cecchini, RS, Geyer, CE, Rastogi, P, Costantino, JP, Atkins, JN, Crown, JP, Polikoff, J, Boileau, JF, Provencher, L, Stokoe, C, Moore, TD, Robidoux, A, Flynn, PJ, Borges, VF, Albain, KS, Swain, SM, Paik, S, Mamounas, EP & Wolmark, N 2020, Journal of Clinical Oncology, vol. 38, no. 5, pp. 444-453. https://doi.org/10.1200/JCO.19.01455

Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial
Golshan, M, Wong, SM, Loibl, S, Huober, JB, OShaughnessy, J, Rugo, HS, Wolmark, N, Ansell, P, Maag, D, Sullivan, DM, Metzger-Filho, O, Von Minckwitz, G, Geyer, CE, Sikov, WM & Untch, M 2020, European Journal of Surgical Oncology, vol. 46, no. 2, pp. 223-228. https://doi.org/10.1016/j.ejso.2019.10.002

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
Swain, SM, Tang, G, Lucas, PC, Robidoux, A, Goerlitz, D, Harris, BT, Bandos, H, Geyer, CE, Rastogi, P, Mamounas, EP & Wolmark, N 2019, Breast Cancer Research and Treatment, vol. 178, no. 2, pp. 389-399. https://doi.org/10.1007/s10549-019-05398-3

Nab-paclitaxel: A new standard of care in neoadjuvant therapy of high-risk early breast cancer?
Ross, M & Geyer, CE 2019, Journal of Clinical Oncology, vol. 37, no. 25, pp. 2196-2200. https://doi.org/10.1200/JCO.19.00877

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
Kim, RS, Song, N, Gavin, PG, Salgado, R, Bandos, H, Kos, Z, Floris, G, Eynden, GGGMVD, Badve, S, Demaria, S, Rastogi, P, Fehrenbacher, L, Mamounas, EP, Swain, SM, Wickerham, DL, Costantino, JP, Paik, S, Wolmark, N, Geyer, CE, Lucas, PC & Pogue-Geile, KL 2019, Journal of the National Cancer Institute, vol. 111, no. 8, pp. 867-871. https://doi.org/10.1093/jnci/djz032

Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer
Sparano, JA, Gray, RJ, Ravdin, PM, Makower, DF, Pritchard, KI, Albain, KS, Hayes, DF, Geyer, CE, Dees, EC, Goetz, MP, Olson, JA, Lively, T, Badve, SS, Saphner, TJ, Wagner, LI, Whelan, TJ, Ellis, MJ, Paik, S, Wood, WC, Keane, MM, Gomez Moreno, HL, Reddy, PS, Goggins, TF, Mayer, IA, Brufsky, AM, Toppmeyer, DL, Kaklamani, VG, Berenberg, JL, Abrams, J & Sledge, GW 2019, New England Journal of Medicine, vol. 380, no. 25, pp. 2395-2405. https://doi.org/10.1056/NEJMoa1904819

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37?298 women with early breast cancer in 26 randomised trials
Early Breast Cancer Trialists Collaborative Group (EBCTCG) 2019, The Lancet, vol. 393, no. 10179, pp. 1440-1452. https://doi.org/10.1016/S0140-6736(18)33137-4

Trastuzumab emtansine for residual invasive HER2-positive breast cancer
Von Minckwitz, G, Huang, CS, Mano, MS, Loibl, S, Mamounas, EP, Untch, M, Wolmark, N, Rastogi, P, Schneeweiss, A, Redondo, A, Fischer, HH, Jacot, W, Conlin, AK, Arce-Salinas, C, Wapnir, IL, Jackisch, C, DiGiovanna, MP, Fasching, PA, Crown, JP, Wülfing, P, Shao, Z, Caremoli, ER, Wu, H, Lam, LH, Tesarowski, D, Smitt, M, Douthwaite, H, Singel, SM & Geyer, CE 2019, New England Journal of Medicine, vol. 380, no. 7, pp. 617-628. https://doi.org/10.1056/NEJMoa1814017

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial
Mamounas, EP, Bandos, H, Lembersky, BC, Jeong, JH, Geyer, CE, Rastogi, P, Fehrenbacher, L, Graham, ML, Chia, SK, Brufsky, AM, Walshe, JM, Soori, GS, Dakhil, SR, Seay, TE, Wade, JL, McCarron, EC, Paik, S, Swain, SM, Wickerham, DL & Wolmark, N 2019, The Lancet Oncology, vol. 20, no. 1, pp. 88-99. https://doi.org/10.1016/S1470-2045(18)30621-1

OpenNotes in oncology: Oncologists’ perceptions and a baseline of the content and style of their clinician notes
Alpert, JM, Morris, BB, Thomson, MD, Matin, K, Geyer, CE & Brown, RF 2019, Translational Behavioral Medicine, vol. 9, no. 2, pp. 347-356. https://doi.org/10.1093/tbm/iby029

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
Geyer, CE, Tang, G, Mamounas, EP, Rastogi, P, Paik, S, Shak, S, Baehner, FL, Crager, M, Wickerham, DL, Costantino, JP & Wolmark, N 2018, npj Breast Cancer, vol. 4, no. 1, 37. https://doi.org/10.1038/s41523-018-0090-6

Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer
Sparano, JA, Gray, RJ, Makower, DF, Pritchard, KI, Albain, KS, Hayes, DF, Geyer, CE, Dees, EC, Goetz, MP, Olson, JA, Lively, T, Badve, SS, Saphner, TJ, Wagner, LI, Whelan, TJ, Ellis, MJ, Paik, S, Wood, WC, Ravdin, PM, Keane, MM, Gomez Moreno, HL, Reddy, PS, Goggins, TF, Mayer, IA, Brufsky, AM, Toppmeyer, DL, Kaklamani, VG, Berenberg, JL, Abrams, J & Sledge, GW 2018, New England Journal of Medicine, vol. 379, no. 2, pp. 111-121. https://doi.org/10.1056/NEJMoa1804710

Tailoring adjuvant endocrine therapy for premenopausal breast cancer
Francis, PA, Pagani, O, Fleming, GF, Walley, BA, Colleoni, M, Láng, I, Gómez, HL, Tondini, C, Ciruelos, E, Burstein, HJ, Bonnefoi, HR, Bellet, M, Martino, S, Geyer, CE, Goetz, MP, Stearns, V, Pinotti, G, Puglisi, F, Spazzapan, S, Climent, MA, Pavesi, L, Ruhstaller, T, Davidson, NE, Coleman, R, Debled, M, Buchholz, S, Ingle, JN, Winer, EP, Maibach, R, Rabaglio-Poretti, M, Ruepp, B, Di Leo, A, Coates, AS, Gelber, RD, Goldhirsch, A & Regan, MM 2018, New England Journal of Medicine, vol. 379, no. 2, pp. 122-137. https://doi.org/10.1056/NEJMoa1803164

Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: Final analysis of the CALOR trial
Wapnir, IL, Price, KN, Anderson, SJ, Robidoux, A, Martín, M, Nortier, JWR, Paterson, AHG, Rimawi, MF, Láng, I, Baena-Cañada, JM, Thürlimann, B, Mamounas, EP, Geyer, CE, Gelber, S, Coates, AS, Gelber, RD, Rastogi, P, Regan, MM, Wolmark, N & Aebi, S 2018, Journal of Clinical Oncology, vol. 36, no. 11, pp. 1073-1079. https://doi.org/10.1200/JCO.2017.76.5719

Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010–2014
Schroeder, MC, Rastogi, P, Geyer, CE, Miller, LD & Thomas, A 2018, Oncologist, vol. 23, no. 4, pp. 481-488. https://doi.org/10.1634/theoncologist.2017-0398

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Loibl, S, OShaughnessy, J, Untch, M, Sikov, WM, Rugo, HS, McKee, MD, Huober, J, Golshan, M, von Minckwitz, G, Maag, D, Sullivan, D, Wolmark, N, McIntyre, K, Ponce Lorenzo, JJ, Metzger Filho, O, Rastogi, P, Symmans, WF, Liu, X & Geyer, CE 2018, The Lancet Oncology, vol. 19, no. 4, pp. 497-509. https://doi.org/10.1016/S1470-2045(18)30111-6

Live Chat Available